SLC2A1 and neoplasm: The glycosyl moiety–enriched Rg3-lipo drug delivery system selectively inhibited tumor cell proliferation and accumulation of MDSCs by targeting Glut1 and Glut3, respectively, promoting an enhanced antitumor immune response.